Xeris Biopharma Holdings, Inc. (XERS)
- Previous Close
1.7600 - Open
1.7600 - Bid 1.7100 x 500
- Ask 1.7300 x 1300
- Day's Range
1.7100 - 1.7800 - 52 Week Range
1.4600 - 3.2600 - Volume
444,271 - Avg. Volume
1,904,422 - Market Cap (intraday)
241.579M - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4500 - Earnings Date Mar 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.75
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
www.xerispharma.comRecent News: XERS
Performance Overview: XERS
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XERS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XERS
Valuation Measures
Market Cap
247.20M
Enterprise Value
403.94M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.48
Price/Book (mrq)
--
Enterprise Value/Revenue
2.46
Enterprise Value/EBITDA
-17.02
Financial Highlights
Profitability and Income Statement
Profit Margin
-37.98%
Return on Assets (ttm)
-8.25%
Return on Equity (ttm)
-324.20%
Revenue (ttm)
163.91M
Net Income Avi to Common (ttm)
-62.26M
Diluted EPS (ttm)
-0.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
72.45M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-19.62M
Research Analysis: XERS
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell